Buerger's disease
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
critical ischaemia
hospital admission + immediate smoking cessation
Patients often present with critical ischaemia and need admission to hospital at the time of diagnosis. Critical ischaemia is defined as gangrene or rest pain lasting >2 weeks and requiring regular opioid analgesia. Its definition may also include ankle pressure of <50 mmHg. Initial admission to hospital involves confirming diagnosis, excluding differential diagnosis, and arterial imaging.
Smoking cessation reduces the incidence of amputation.[2]Le Joncour A, Soudet S, Dupont A, et al. Long-term outcome and prognostic factors of complications in thromboangiitis obliterans (Buerger's disease): a multicenter study of 224 patients. J Am Heart Assoc. 2018 Dec 4;7(23):e010677. https://www.doi.org/10.1161/JAHA.118.010677 http://www.ncbi.nlm.nih.gov/pubmed/30571594?tool=bestpractice.com [5]Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation. 1990 Nov;82(5 suppl):IV3-8. http://www.ncbi.nlm.nih.gov/pubmed/2225420?tool=bestpractice.com It improves patency and limb salvage rates in those who do undergo surgical revascularisation.[31]Sasajima T, Kubo Y, Inaba M, et al. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur J Vasc Endovasc Surg. 1997 Feb;13(2):186-92. http://www.ncbi.nlm.nih.gov/pubmed/9091153?tool=bestpractice.com [32]Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004 Jan;39(1):176-80. http://www.ncbi.nlm.nih.gov/pubmed/14718836?tool=bestpractice.com From a group of 43 patients who stopped smoking, 94% avoided an amputation.[33]Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med. 2000 Jan;343(1):864-9. http://www.ncbi.nlm.nih.gov/pubmed/10995867?tool=bestpractice.com Patients who continue to smoke have a 19% major amputation rate; this is 2.73 times greater than for people who have ceased smoking, according to one study.[32]Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004 Jan;39(1):176-80. http://www.ncbi.nlm.nih.gov/pubmed/14718836?tool=bestpractice.com [34]Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. Int J Cardiol. 2000 Aug 31;75(suppl 1):S175-81. http://www.ncbi.nlm.nih.gov/pubmed/10980360?tool=bestpractice.com Smoking increases flare-ups and reduces ulcer healing. A return to smoking following cessation may lead to a flare-up of the disease. Smoking only 1 or 2 cigarettes a day, using smokeless tobacco (chewing tobacco), or using nicotine replacement therapy may all keep the disease active.[19]Lie JT. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum. 1988 Jun;31(6):812-3. http://www.ncbi.nlm.nih.gov/pubmed/3382454?tool=bestpractice.com [20]Joyce JW. Buerger's disease (thromboangiitis obliterans). Rheum Dis Clin North Am. 1990 May;16(2):463-70. http://www.ncbi.nlm.nih.gov/pubmed/2189162?tool=bestpractice.com
For more information see the BMJ Best Practice topic 'Smoking Cessation'.
vasoactive medication
Treatment recommended for ALL patients in selected patient group
Vasoactive dilation (e.g., with nifedipine) is done during initial admission to hospital, along with debridement of any gangrenous tissue. Further treatments are given depending on severity of ischaemia and degree of pain. Pentoxifylline and cilostazol have had good effects, although there is little supportive data. They are not routinely used. Pentoxifylline has been shown to improve pain and healing in ischaemic ulcers.[37]Agarwal P, Agrawal PK, Sharma D, et al. Intravenous infusion for the treatment of diabetic and ischaemic non-healing pedal ulcers. J Eur Acad Dermatol Venereol. 2005 Mar;19(2):158-62. http://www.ncbi.nlm.nih.gov/pubmed/15752282?tool=bestpractice.com Treatment with pentoxifylline can be tried after other medical therapies have failed. Cilostazol could be tried in conjunction with or following failure of other medical therapies (e.g., nifedipine).[38]Ohashi S, Iwatani M, Hyakuna Y, et al. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. Arzneimittelforschung. 1985;35(7A):1203-8. http://www.ncbi.nlm.nih.gov/pubmed/4074436?tool=bestpractice.com It is contra-indicated in the following: patients with unstable angina, recent myocardial infarction, or coronary intervention (within 6 months); patients receiving 2 or more other antiplatelet agents or anticoagulants; and patients with history of severe tachyarrhythmia.
Intravenous iloprost may improve ulcer healing rates, but is not available in many countries.
Primary options
nifedipine: 5 mg orally (immediate-release) three times daily initially, increase according to response, maximum 120 mg/day; 30 mg orally (extended-release) once daily initially, increase according to response, maximum 90 mg/day
Secondary options
pentoxifylline: consult specialist for guidance on dose
OR
cilostazol: consult specialist for guidance on dose
surgical debridement
Additional treatment recommended for SOME patients in selected patient group
Vasoactive dilation is done during initial admission to hospital, along with debridement of any gangrenous tissue.
intravenous antibiotic therapy
Additional treatment recommended for SOME patients in selected patient group
Antibiotics are indicated only in the presence of infection or wet gangrene. Aerobic and anaerobic cover is needed.
Regimens include a penicillin plus metronidazole, or ciprofloxacin (if Pseudomonas is present), or a third-generation cephalosporin plus metronidazole. However, local protocols should be followed.
Primary options
metronidazole: 500 mg intravenously every 6-8 hours
and
benzylpenicillin sodium: 900 mg intravenously every 6 hours
OR
ciprofloxacin: 400 mg intravenously every 12 hours
OR
cefuroxime: 750 mg intravenously every 8 hours
and
metronidazole: 500 mg intravenously every 6-8 hours
analgesia
Additional treatment recommended for SOME patients in selected patient group
For acute ischaemic pain, paracetamol and an opioid (weak or strong) are recommended, depending on the severity of pain.[43]National Institute for Health and Care Excellence. Peripheral arterial disease: diagnosis and management. NICE clinical guideline CG147. Dec 2020 [internet publication]. https://www.nice.org.uk/guidance/cg147 Severe pain often requires admission to hospital so that disease can be controlled or the extent of disease can be assessed.
Primary options
paracetamol: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
-- AND --
codeine phosphate: 30-60 mg orally every 4 hours when required, maximum 240 mg/day
or
morphine sulfate: 10-30 mg orally (immediate-release) every 4 hours when required, titrate dose according to response; 2.5 to 10 mg subcutaneously/intramuscularly/intravenously every 2-6 hours when required, titrate dose according to response
spinal cord stimulation
Additional treatment recommended for SOME patients in selected patient group
Spinal cord stimulation may be beneficial in alleviating ischaemic pain. It is performed by an implantable stimulator.[44]Donas KP, Schulte S, Ktenidis K, et al. The role of epidural spinal cord stimulation in the treatment of Buerger's disease. J Vasc Surg. 2005 May;41(5):830-6. http://www.ncbi.nlm.nih.gov/pubmed/15886668?tool=bestpractice.com [45]Manfredini R, Boari B, Gallerani M, et al. Thromboangiitis obliterans (Buerger disease) in a female mild smoker treated with spinal cord stimulation. Am J Med Sci. 2004 Jun;327(6):365-8. http://www.ncbi.nlm.nih.gov/pubmed/15201654?tool=bestpractice.com [46]Broseta J, Barbera J, de Vera JA, et al. Spinal cord stimulation in peripheral arterial disease: a cooperative study. J Neurosurg. 1986 Jan;64(1):71-80. http://www.ncbi.nlm.nih.gov/pubmed/3484519?tool=bestpractice.com
intravenous guanethidine
Additional treatment recommended for SOME patients in selected patient group
Guanethidine reduces catecholamine release by acting on the Na+-ATPase-dependent pump. Reduction of rest pain and ulceration healing have been reported with guanethidine injections into the affected limb, sometimes with the additional use of a Bier block (intravenous regional sympathetic blockade).[47]Stümpflen A, Ahmadi A, Attender M, et al. Effects of transvenous regional guanethidine block in the treatment of critical finger ischemia. Angiology. 2000 Feb;51(2):115-22. http://www.ncbi.nlm.nih.gov/pubmed/10701719?tool=bestpractice.com [48]Paraskevas KI, Trigka AA, Samara M. Successful intravenous regional sympathetic blockade (Bier's Block) with guanethidine and lidocaine in a patient with advanced Buerger's Disease (thromboangiitis obliterans) - a case report. Angiology. 2005 Jul-Aug;56(4):493-6. http://www.ncbi.nlm.nih.gov/pubmed/16079935?tool=bestpractice.com Injections can be easily repeated if beneficial effects are seen.
Data on the effectiveness of guanethidine are limited, and it is not available in many countries.
surgical revascularisation/amputation
Additional treatment recommended for SOME patients in selected patient group
Due to the lack of patent distal vessels, bypass is often not an option. Angiography may reveal potential distal anastomotic sites, allowing bypass to help ulcer healing. However, primary graft patency rates are 41% at 1 year, 32% at 5 years, and 30% at 10 years; secondary patency rates are 54% at 1 year, 47% at 5 years, and 39% at 10 years.[32]Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004 Jan;39(1):176-80. http://www.ncbi.nlm.nih.gov/pubmed/14718836?tool=bestpractice.com
Surgical revascularisation is indicated mainly in patients with critical ischaemia. Patients with non-critical ischaemia are indicated for surgical revascularisation only if there is severe claudication and a good vessel to anastomose onto distally.
If part of a limb is clearly non-viable from the outset or attempts at revascularisation should fail, amputation is required. Careful consideration of the most appropriate type and level of amputation should be made in consultation with the patient, bearing in mind factors such as likelihood of successful healing, patient motivation and social circumstances, and the patient's potential functional outcomes with an appropriate prosthesis, if required.
non-critical ischaemia
urgent smoking cessation
Patients with non-critical ischaemia present with either claudication or new onset of rest pain.
Smoking cessation reduces the incidence of amputation.[2]Le Joncour A, Soudet S, Dupont A, et al. Long-term outcome and prognostic factors of complications in thromboangiitis obliterans (Buerger's disease): a multicenter study of 224 patients. J Am Heart Assoc. 2018 Dec 4;7(23):e010677. https://www.doi.org/10.1161/JAHA.118.010677 http://www.ncbi.nlm.nih.gov/pubmed/30571594?tool=bestpractice.com [5]Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation. 1990 Nov;82(5 suppl):IV3-8. http://www.ncbi.nlm.nih.gov/pubmed/2225420?tool=bestpractice.com It improves patency and limb salvage rates in those who do undergo surgical revascularisation.[31]Sasajima T, Kubo Y, Inaba M, et al. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur J Vasc Endovasc Surg. 1997 Feb;13(2):186-92. http://www.ncbi.nlm.nih.gov/pubmed/9091153?tool=bestpractice.com [32]Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004 Jan;39(1):176-80. http://www.ncbi.nlm.nih.gov/pubmed/14718836?tool=bestpractice.com From a group of 43 patients who stopped smoking, 94% avoided an amputation.[33]Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med. 2000 Jan;343(1):864-9. http://www.ncbi.nlm.nih.gov/pubmed/10995867?tool=bestpractice.com
Patients who continue to smoke have a 19% major amputation rate; this is 2.73 times greater than for people who have ceased smoking, according to one study.[32]Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004 Jan;39(1):176-80. http://www.ncbi.nlm.nih.gov/pubmed/14718836?tool=bestpractice.com [34]Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. Int J Cardiol. 2000 Aug 31;75(suppl 1):S175-81. http://www.ncbi.nlm.nih.gov/pubmed/10980360?tool=bestpractice.com
Smoking increases flare-ups and reduces ulcer healing. A return to smoking following cessation may lead to a flare-up of the disease.
Smoking only 1 or 2 cigarettes a day, using smokeless tobacco (chewing tobacco), or using nicotine replacement therapy may all keep the disease active.[19]Lie JT. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum. 1988 Jun;31(6):812-3. http://www.ncbi.nlm.nih.gov/pubmed/3382454?tool=bestpractice.com [20]Joyce JW. Buerger's disease (thromboangiitis obliterans). Rheum Dis Clin North Am. 1990 May;16(2):463-70. http://www.ncbi.nlm.nih.gov/pubmed/2189162?tool=bestpractice.com
vasoactive medication
Additional treatment recommended for SOME patients in selected patient group
Nifedipine, a calcium-channel blocker, may cause peripheral vasodilation and improve distal blood flow.[5]Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation. 1990 Nov;82(5 suppl):IV3-8. http://www.ncbi.nlm.nih.gov/pubmed/2225420?tool=bestpractice.com
It has been shown to be of benefit in patients with lower limb trophic changes and symptoms, and is often given in combination with other therapies, such as cessation of smoking, antibiotics, and iloprost.[35]O'Dell JR, Linder J, Markin RS, et al. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum. 1987 Sep;30(9):1054-6. http://www.ncbi.nlm.nih.gov/pubmed/3663253?tool=bestpractice.com [36]Palomo Arellano A, Gomez Tello V, Parilla Herranz P, et al. Buerger's disease starting in the upper extremity: a favorable response to nifedipine treatment combined with stopping tobacco use. An Med Interna. 1990 Jun;7(6):307-8. http://www.ncbi.nlm.nih.gov/pubmed/2102735?tool=bestpractice.com
Pentoxifylline and cilostazol are vaso-active drugs that have had good effects, although there are few supportive data. They are not routinely used. Pentoxifylline has been shown to improve pain and healing in ischaemic ulcers.[37]Agarwal P, Agrawal PK, Sharma D, et al. Intravenous infusion for the treatment of diabetic and ischaemic non-healing pedal ulcers. J Eur Acad Dermatol Venereol. 2005 Mar;19(2):158-62. http://www.ncbi.nlm.nih.gov/pubmed/15752282?tool=bestpractice.com Treatment with pentoxifylline can be tried after other medical therapies have failed. Cilostazol could be tried in conjunction with or following failure of other medical therapies (e.g., nifedipine).[38]Ohashi S, Iwatani M, Hyakuna Y, et al. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. Arzneimittelforschung. 1985;35(7A):1203-8. http://www.ncbi.nlm.nih.gov/pubmed/4074436?tool=bestpractice.com It is contraindicated in the following: patients with unstable angina, recent myocardial infarction, or coronary intervention (within 6 months); patients receiving 2 or more other antiplatelet agents or anticoagulants; and patients with history of severe tachyarrhythmia.
Intravenous iloprost may improve ulcer healing rates, but is not available in many countries.
Primary options
nifedipine: 5 mg orally (immediate-release) three times daily initially, increase according to response, maximum 120 mg/day; 30 mg orally (extended-release) once daily initially, increase according to response, maximum 90 mg/day
Secondary options
pentoxifylline: consult specialist for guidance on dose
OR
cilostazol: consult specialist for guidance on dose
oral antibiotic therapy
Additional treatment recommended for SOME patients in selected patient group
Antibiotics are indicated only in the presence of infection or wet gangrene. Aerobic and anaerobic cover is needed.
Amoxicillin/clavulanate may be adequate, or a penicillin plus metronidazole, or ciprofloxacin (if Pseudomonas is present), or a third-generation cephalosporin plus metronidazole. However, local protocols should be followed.
Primary options
metronidazole: 500 mg orally three times daily
and
phenoxymethylpenicillin: 500 mg orally four times a day
OR
amoxicillin/clavulanate: 500 mg orally three times daily
More amoxicillin/clavulanateDose refers to amoxicillin component.
OR
ciprofloxacin: 500 mg orally twice daily
OR
cefuroxime: 250-500 mg orally twice daily
and
metronidazole: 500 mg orally three times daily
analgesia
Additional treatment recommended for SOME patients in selected patient group
For acute ischaemic pain, paracetamol and an opioid (weak or strong) are recommended, depending on the severity of pain.[43]National Institute for Health and Care Excellence. Peripheral arterial disease: diagnosis and management. NICE clinical guideline CG147. Dec 2020 [internet publication]. https://www.nice.org.uk/guidance/cg147
Non-steroidal anti-inflammatory drugs (NSAIDs) can be used to treat superficial venous thrombophlebitis.
Primary options
paracetamol: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
-- AND --
codeine phosphate: 30-60 mg orally every 4 hours when required, maximum 240 mg/day
or
morphine sulfate: 10-30 mg orally (immediate-release) every 4 hours when required, titrate dose according to response; 2.5 to 10 mg subcutaneously/intramuscularly/intravenously every 2-6 hours when required, titrate dose according to response
Secondary options
ibuprofen: 300-400 mg orally every 6-8 hours when required, maximum 2400 mg/day
OR
diclofenac potassium: 50 mg orally (immediate-release) two or three times daily
spinal cord stimulation
Additional treatment recommended for SOME patients in selected patient group
Spinal cord stimulation may be beneficial in alleviating ischaemic pain. It has been shown to be of benefit in patients with lower limb symptoms ranging from claudication and pain to ulceration and trophic changes. Often used after medical therapy has failed. Spinal cord stimulation is performed by an implantable stimulator.[44]Donas KP, Schulte S, Ktenidis K, et al. The role of epidural spinal cord stimulation in the treatment of Buerger's disease. J Vasc Surg. 2005 May;41(5):830-6. http://www.ncbi.nlm.nih.gov/pubmed/15886668?tool=bestpractice.com [45]Manfredini R, Boari B, Gallerani M, et al. Thromboangiitis obliterans (Buerger disease) in a female mild smoker treated with spinal cord stimulation. Am J Med Sci. 2004 Jun;327(6):365-8. http://www.ncbi.nlm.nih.gov/pubmed/15201654?tool=bestpractice.com [46]Broseta J, Barbera J, de Vera JA, et al. Spinal cord stimulation in peripheral arterial disease: a cooperative study. J Neurosurg. 1986 Jan;64(1):71-80. http://www.ncbi.nlm.nih.gov/pubmed/3484519?tool=bestpractice.com
sympathectomy
Additional treatment recommended for SOME patients in selected patient group
Sympathectomy can be chemical or surgical, lumbar, or thorascopic. Both positive and negative results have been reported with lumbar sympathectomy.[49]Chander J, Singh L, Lal P, et al. Retroperitoneoscopic lumbar sympathectomy for Buerger's disease: a novel technique. JSLS. 2004 Jul-Sep;8(3):291-6. http://www.ncbi.nlm.nih.gov/pubmed/15347122?tool=bestpractice.com [40]Bozkurt AK, Koksal C, Demirbas MY, et al. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol. 2006 Jun;25(2):162-8. http://www.ncbi.nlm.nih.gov/pubmed/16763533?tool=bestpractice.com
Sympathectomy may be sufficient to enable necrotic lesions to heal.[50]Lau H, Cheng SW. Buerger's disease in Hong Kong: a review of 89 cases. Aust NZ J Surg. 1997 May;67(5):264-9. http://www.ncbi.nlm.nih.gov/pubmed/9152156?tool=bestpractice.com It is thought to reduce pain by reducing peripheral resistance and promoting collateral development.[51]Kothari R, Sharma D, Thakur DS, et al. Thoracoscopic dorsal sympathectomy for upper limb Buerger's disease. JSLS. 2014 Apr-Jun;18(2):273-6. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035639 http://www.ncbi.nlm.nih.gov/pubmed/24960492?tool=bestpractice.com
Thorascopic sympathectomy can be used for upper limb symptoms, and lumbar sympathectomy for lower limb symptoms. Due to the invasiveness of the procedure, sympathectomy is often a treatment tried when medical therapy has failed and there is no revascularisation option. Often used in the more severe cases where there is tissue loss. However, its use has been reported in patients presenting with claudication.[52]Segers B, Himpens J, Barroy JP. Retroperitoneal laparoscopic bilateral lumbar sympathectomy. Acta Chir Belg. 2007 Jun;107(3):341-2. http://www.ncbi.nlm.nih.gov/pubmed/17685269?tool=bestpractice.com
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer